troglitazone has been researched along with Glioma in 6 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | 5.34 | The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| " Agonists of the peroxisome proliferator-activated receptor-gamma (PPARgamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules." | 3.73 | Rosiglitazone ameliorates cisplatin-induced renal injury in mice. ( Jang, KY; Jang, YB; Kang, KP; Kim, DH; Kim, W; Lee, JE; Lee, S; Moon, SO; Park, SK; Sung, MJ, 2006) |
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | 1.34 | The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grund, K | 1 |
| Ahmadi, R | 1 |
| Jung, F | 1 |
| Funke, V | 1 |
| Gdynia, G | 1 |
| Benner, A | 1 |
| Sykora, J | 1 |
| Walczak, H | 1 |
| Joos, S | 1 |
| Felsberg, J | 1 |
| Reifenberger, G | 1 |
| Wiestler, OD | 1 |
| Herold-Mende, C | 1 |
| Roth, W | 1 |
| Hollander, AB | 1 |
| Dorsey, JF | 1 |
| Akasaki, Y | 1 |
| Liu, G | 1 |
| Matundan, HH | 1 |
| Ng, H | 1 |
| Yuan, X | 1 |
| Zeng, Z | 1 |
| Black, KL | 1 |
| Yu, JS | 1 |
| Lee, S | 1 |
| Kim, W | 1 |
| Moon, SO | 1 |
| Sung, MJ | 1 |
| Kim, DH | 1 |
| Kang, KP | 1 |
| Jang, YB | 1 |
| Lee, JE | 1 |
| Jang, KY | 1 |
| Park, SK | 1 |
| Spagnolo, A | 1 |
| Grant, EN | 1 |
| Glick, R | 1 |
| Lichtor, T | 1 |
| Feinstein, DL | 1 |
| Coras, R | 1 |
| Hölsken, A | 1 |
| Seufert, S | 1 |
| Hauke, J | 1 |
| Eyüpoglu, IY | 1 |
| Reichel, M | 1 |
| Tränkle, C | 1 |
| Siebzehnrübl, FA | 1 |
| Buslei, R | 1 |
| Blümcke, I | 1 |
| Hahnen, E | 1 |
6 other studies available for troglitazone and Glioma
| Article | Year |
|---|---|
Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD.
Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; CASP8 and FADD-Like Apoptosis Regula | 2008 |
FLIPing the apoptosis switch on in brain tumors using Troglitazone and TRAIL.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Chromans; Glioblastoma; Glioma; Humans; | 2008 |
A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspase 8; Caspase 9; Caspases; Chr | 2006 |
Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
Topics: Anilides; Animals; Apoptosis; C-Peptide; Cell Line; Chromans; Cisplatin; Drug Evaluation, Preclinica | 2006 |
Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Surv | 2007 |
The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Chromans; DNA Primers; Dow | 2007 |